Monopar Therapeutics (MNPR) Competitors $43.15 +1.33 (+3.18%) Closing price 04:00 PM EasternExtended Trading$43.30 +0.16 (+0.36%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNPR vs. SNDX, BGM, ADPT, IOVA, WVE, ETNB, COLL, MLYS, NTLA, and SYREShould you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Syndax Pharmaceuticals (SNDX), Qilian International Holding Group (BGM), Adaptive Biotechnologies (ADPT), Iovance Biotherapeutics (IOVA), Wave Life Sciences (WVE), 89bio (ETNB), Collegium Pharmaceutical (COLL), Mineralys Therapeutics (MLYS), Intellia Therapeutics (NTLA), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry. Monopar Therapeutics vs. Syndax Pharmaceuticals Qilian International Holding Group Adaptive Biotechnologies Iovance Biotherapeutics Wave Life Sciences 89bio Collegium Pharmaceutical Mineralys Therapeutics Intellia Therapeutics Spyre Therapeutics Syndax Pharmaceuticals (NASDAQ:SNDX) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership, community ranking and valuation. Do analysts rate SNDX or MNPR? Syndax Pharmaceuticals currently has a consensus target price of $36.20, suggesting a potential upside of 161.94%. Monopar Therapeutics has a consensus target price of $55.33, suggesting a potential upside of 28.23%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Syndax Pharmaceuticals is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Monopar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the MarketBeat Community favor SNDX or MNPR? Syndax Pharmaceuticals received 345 more outperform votes than Monopar Therapeutics when rated by MarketBeat users. However, 73.02% of users gave Monopar Therapeutics an outperform vote while only 65.38% of users gave Syndax Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSyndax PharmaceuticalsOutperform Votes39165.38% Underperform Votes20734.62% Monopar TherapeuticsOutperform Votes4673.02% Underperform Votes1726.98% Which has more volatility and risk, SNDX or MNPR? Syndax Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Which has stronger valuation & earnings, SNDX or MNPR? Monopar Therapeutics has lower revenue, but higher earnings than Syndax Pharmaceuticals. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyndax Pharmaceuticals$23.68M50.22-$209.36M-$3.73-3.71Monopar TherapeuticsN/AN/A-$8.40M-$3.60-11.99 Do institutionals and insiders believe in SNDX or MNPR? 1.8% of Monopar Therapeutics shares are owned by institutional investors. 4.1% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 34.9% of Monopar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media refer more to SNDX or MNPR? In the previous week, Syndax Pharmaceuticals had 4 more articles in the media than Monopar Therapeutics. MarketBeat recorded 7 mentions for Syndax Pharmaceuticals and 3 mentions for Monopar Therapeutics. Syndax Pharmaceuticals' average media sentiment score of 1.28 beat Monopar Therapeutics' score of 0.58 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monopar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SNDX or MNPR more profitable? Syndax Pharmaceuticals' return on equity of -64.34% beat Monopar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Syndax PharmaceuticalsN/A -64.34% -57.72% Monopar Therapeutics N/A -107.21%-87.57% SummarySyndax Pharmaceuticals beats Monopar Therapeutics on 11 of the 16 factors compared between the two stocks. Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNPR vs. The Competition Export to ExcelMetricMonopar TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$263.78M$6.71B$5.49B$7.95BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-21.907.3522.6218.58Price / SalesN/A241.98397.85103.49Price / CashN/A65.8538.1834.62Price / Book22.956.496.744.25Net Income-$8.40M$143.41M$3.22B$248.18M7 Day Performance-3.19%2.24%1.59%1.36%1 Month Performance29.08%7.16%4.09%3.85%1 Year Performance1,227.69%-2.45%15.98%5.37% Monopar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNPRMonopar Therapeutics2.8845 of 5 stars$43.15+3.2%$55.33+28.2%+1,167.1%$263.78MN/A-21.9010Upcoming EarningsNews CoverageGap DownSNDXSyndax Pharmaceuticals3.6563 of 5 stars$11.93+3.4%$36.20+203.4%-33.0%$1.03B$23.68M-3.29110Upcoming EarningsPositive NewsBGMQilian International Holding GroupN/A$10.52-4.4%N/AN/A$1.02B$25.10M0.00298ADPTAdaptive Biotechnologies4.1439 of 5 stars$6.83-6.8%$9.40+37.6%+180.9%$1.01B$178.96M-6.27790News CoveragePositive NewsGap DownIOVAIovance Biotherapeutics4.5731 of 5 stars$3.08+0.7%$18.22+491.6%-69.5%$1.01B$164.07M-2.07500Upcoming EarningsWVEWave Life Sciences4.3154 of 5 stars$6.12+3.4%$22.18+262.4%+56.6%$939.33M$108.30M-5.51240Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageETNB89bio2.9783 of 5 stars$6.27+3.5%$27.56+339.5%-5.8%$915.32MN/A-2.1540Upcoming EarningsAnalyst UpgradeNews CoveragePositive NewsCOLLCollegium Pharmaceutical4.0384 of 5 stars$26.91-0.4%$43.60+62.0%-26.9%$864.67M$631.45M11.60210Upcoming EarningsPositive NewsMLYSMineralys Therapeutics2.3833 of 5 stars$13.24-0.8%$33.00+149.2%+16.0%$858.96MN/A-3.6428Upcoming EarningsShort Interest ↑NTLAIntellia Therapeutics4.5482 of 5 stars$7.92+9.5%$36.68+363.2%-58.6%$819.86M$57.88M-1.46600Upcoming EarningsPositive NewsHigh Trading VolumeSYRESpyre Therapeutics1.9151 of 5 stars$13.57+7.1%$49.57+265.3%-53.9%$817.95M$890,000.00-1.82100Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies Syndax Pharmaceuticals Alternatives Qilian International Holding Group Alternatives Adaptive Biotechnologies Alternatives Iovance Biotherapeutics Alternatives Wave Life Sciences Alternatives 89bio Alternatives Collegium Pharmaceutical Alternatives Mineralys Therapeutics Alternatives Intellia Therapeutics Alternatives Spyre Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNPR) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MNPR Stock Free MNPR Stock Alerts